Equality impact assessment – Guidance development

Single Technology Appraisal

Trastuzumab for the treatment of HER2-positive metastatic gastric cancer

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

At the scoping stage it was highlighted that there may be some equalities issues with certain social groups who are known to have a high incidence of gastric cancer. The Committee considered the variation in incidence of gastric cancer but did not consider that their recommendations would lead to differential access to the technology according to social class.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these?

There was only one equalities issue raised during this appraisal and this was the higher incidence of gastric cancer in some social groups. The Committee did not consider that access to the technology would differ according to incidence rates.

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?
No other potential equality issues identified.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

No barriers to accessing this technology were identified during the appraisal process.

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE’s obligations to promote equality?

Not applicable.

6. Have the Committee’s considerations of equality issues been described in the appraisal consultation document, and, if so, where?

No equalities and diversities issues affecting access to treatments were raised in the submissions for this appraisal. The Committee’s considerations were described in the summary table of the Committee’s key conclusions.

Approved by Associate Director (name): Frances Sutcliffe

Date: 19 November 2010

Final appraisal determination

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

The Committee heard that the incidence of gastric cancer is increased in certain social classes but did not consider that the recommendations would
lead to differential access to the technology according to social class.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

No change to recommendations after consultation.

3. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE’s obligations to promote equality?

No change to recommendations after consultation.

4. Have the Committee’s considerations of equality issues been described in the final appraisal determination, and, if so, where?

The Committee’s considerations were described in the summary table of the Committee’s key conclusions.

Approved by Centre or Programme Director (name): Meindert Boysen

Date: 22 November 2010